220 F. Supp. 3d 736
N.D. Tex.2016Background
- Decedent died of fentanyl toxicity after using a FDA‑approved generic fentanyl transdermal patch marketed by Mylan; plaintiffs (her husband and children/estate) sued the Mylan entities in Texas state‑law product liability and related claims.
- Plaintiffs allege the patch malfunctioned (manufacturing defect), was defectively designed, and lacked adequate warnings, causing a lethal fentanyl blood level.
- Plaintiffs pleaded claims for strict product liability (Restatement §402A), negligence, negligent misrepresentation, breach of implied warranties (fitness and merchantability), DTPA violations, and gross negligence.
- Defendants moved to dismiss under Rule 12(b)(6), arguing plaintiffs’ factual pleading is inadequate for manufacturing defect claims and that design/warning‑based claims are preempted by federal law because the product is a generic required to match the brand drug’s labeling and composition.
- The court took judicial notice of the FDA approval letter and the product label (including a black‑box warning) and dismissed: design/warning‑based claims and related counts with prejudice (federal preemption); manufacturing‑defect and certain warranty/failure‑to‑notify allegations without prejudice; plaintiffs were granted leave to amend limited claims.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Sufficiency of manufacturing defect allegations | The lethal fentanyl level shows the patch malfunctioned (manufacturing defect) | Plaintiffs plead only res ipsa‑style conclusions, no specific manufacturing defect | Dismissed without prejudice — conclusory pleadings insufficient under Twombly/Iqbal; cannot infer defect from accident alone |
| Failure‑to‑warn and design‑defect (state law) | Mylan failed to warn/defectively design the patch causing death | Federal FDCA duty of sameness for generics precludes changing label or design; such state claims conflict with federal law | Dismissed with prejudice — preempted by Mensing/Bartlett and Fifth Circuit precedent |
| Fraud‑on‑FDA exception to Texas §82.007 (rebut presumption of compliance) | Plaintiffs allege defendants withheld safety information from FDA | Defendants assert plaintiffs do not allege an FDA finding of fraud; Lofton bars the exception absent such a finding | Dismissed with prejudice — plaintiffs did not plead an FDA finding of fraud, so cannot overcome statutory presumption |
| Breach of implied warranty of fitness/merchantability and related statutory prerequisites | Patch was unfit for its intended use and breached warranties | Plaintiff used the patch for its ordinary purpose; also failed to allege pre‑suit notice required for warranty claims | Warranty claims dismissed (fitness claim without prejudice; merchantability and related warranty claims dismissed — also dismissed for failure to give statutory pre‑suit notice) |
Key Cases Cited
- Bell Atl. Corp. v. Twombly, 550 U.S. 544 (establishes plausibility pleading standard)
- Ashcroft v. Iqbal, 556 U.S. 662 (applies plausibility standard to complaints)
- Mut. Pharm. Co. v. Bartlett, 133 S. Ct. 2466 (federal duty of sameness preempts state design‑change claims against generic manufacturers)
- PLIVA, Inc. v. Mensing, 564 U.S. 604 (failure‑to‑warn claims against generics are preempted by federal law)
- Funk v. Stryker Corp., 631 F.3d 777 (res ipsa allegations insufficient for manufacturing‑defect claims in product‑liability context)
- Lofton v. McNeil Consumer & Specialty Pharm., 672 F.3d 372 (fraud‑on‑the‑FDA exception to state presumption is preempted absent FDA finding of fraud)
- Uniroyal Goodrich Tire Co. v. Martinez, 977 S.W.2d 328 (Tex.) (Texas follows Restatement (Second) §402A for product liability)
- Ford Motor Co. v. Ridgway, 135 S.W.3d 598 (Tex.) (cannot infer defect from accident alone)
- Eckhardt v. Qualitest Pharm. Inc., 751 F.3d 674 (5th Cir.) (generic‑drug failure‑to‑warn/design claims preempted; pleading requirements explained)